Opinion|Videos|August 19, 2024
Talking to Patients about Atopic Dermatitis Treatment Response
Lindsay S. Ackerman, MD, FAAD, provides clinical insights on best practices for evaluating treatment response in patients with atopic dermatitis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When choosing treatment or evaluating treatment response, what questions are most important to ask patients?
- Do you talk to patients about EASI 75/90/100, pruritus NRS 0/1, or percentage improvement in scores, etc. when evaluating response to treatment?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5